PCM
CNTA

Prelude Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Prelude Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,656
Closed -$646K – 1331
2025
Q3 		$646K Sell
26,656
-23,444
-47% -$417K 0.05% 433
2025
Q2 		$658K Buy
50,100
+14,300
+40% +$181K 0.06% 365
2025
Q1 		$515K Hold
35,800
– – 0.04% 510
2024
Q4 		$600K Sell
35,800
-1,100
-3% -$18.2K 0.04% 530
2024
Q3 		$590K Sell
36,900
-32,000
-46% -$392K 0.04% 563
2024
Q2 		$622K Sell
68,900
-209
-0.3% -$1.98K 0.04% 451
2024
Q1 		$781K Buy
+69,109
New +$654K 0.04% 464
2022
Q2 		– Sell
-11,400
Closed -$102K – 1835
2022
Q1 		$102K Buy
+11,400
New +$104K ﹤0.01% 1406

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Prelude Capital Management's CNTA Position: Q4 2025 in Review

Prelude Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 26,656 shares — an estimated $646K sold.

Prelude Capital Management first reported a position in CNTA in Q1 2022 and held it in 8 quarters. The position peaked at $781K in Q1 2024. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Prelude Capital Management reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Prelude Capital Management sold 26,656 Centessa Pharmaceuticals shares in Q4 2025, an estimated $646K.
  • Prelude Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2022 and held it in 8 quarters.
  • Prelude Capital Management's Centessa Pharmaceuticals position peaked at $781K in Q1 2024.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.